Search

Your search keyword '"Blankenbiller, Tricia"' showing total 19 results
Start Over Author "Blankenbiller, Tricia"
19 results on '"Blankenbiller, Tricia"'

12. Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine (P4.093)

Author

Dodick, David, primary, Aycardi, Ernesto, additional, Bigal, Marcelo, additional, Yeung, Paul P., additional, Blankenbiller, Tricia, additional, Grozinski-Wolff, Melissa, additional, Yang, Ronghua, additional, Ma, Yuju, additional, Silberstein, Stephen, additional, and Goadsby, Peter J., additional

Published
2018
Full Text
View/download PDF

17. Baseline Characteristics And Interim Analysis Results Of The Fingolimod Cohort In The World-Wide Post-Approval Safety Program (PASSAGE) (P2.202)

Author

Giacomini, Paul, primary, Butzkueven, Helmut, additional, Cohan, Stanley, additional, Olsson, Tomas, additional, Rothenbacher, Dietrich, additional, Weller, Belinda, additional, Ziemssen, Tjalf, additional, Gupta, Anu, additional, Cremer, Malika, additional, Blankenbiller, Tricia, additional, Rochotte, Erika, additional, Tomic, Davorka, additional, Von Rosenstiel, Philipp, additional, and Trojano, Maria, additional

Published
2014
Full Text
View/download PDF

19. Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.

Author

Brandes, Jan Lewis, Kudrow, David, Yeung, Paul P, Sakai, Fumihiko, Aycardi, Ernesto, Blankenbiller, Tricia, Grozinski-Wolff, Melissa, Yang, Ronghua, and Ma, Yuju

Subjects
*MIGRAINE, *CALCITONIN gene-related peptide, *HEADACHE, *DRUGS, *MONOCLONAL antibodies
Abstract

Background: Fremanezumab, a fully humanized monoclonal antibody targeting calcitonin gene-related peptide, has demonstrated efficacy for the preventive treatment of migraine in adults. Objective: To evaluate the effect of fremanezumab treatment on acute headache medication use and migraine-associated symptoms in patients with episodic migraine. Methods: In the Phase 3 HALO trial, patients with episodic migraine were randomized to receive subcutaneous fremanezumab monthly (225 mg at baseline, weeks 4 and 8), fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8), or placebo over a 12-week period. The secondary endpoint was change from baseline in the monthly number of days with use of any acute headache mediation or migraine-specific acute headache medication; exploratory endpoints were change from baseline in the monthly number of days with nausea or vomiting, photophobia, or phonophobia. Results: Of 875 patients randomized, 865 were included in the analysis (monthly, n = 287; quarterly, n = 288; placebo, n = 290). Baseline mean ± standard deviation days with: Any acute headache medication use (monthly: 7.7 ± 3.4; quarterly: 7.8 ± 3.7; placebo: 7.7 ± 3.6), migraine-specific acute headache medication use (6.1 ± 3.1; 6.6 ± 3.1; 7.1 ± 3.0), nausea or vomiting (4.5 ± 3.6; 4.9 ± 3.7; 4.5 ± 3.3) and photophobia and phonophobia (5.5 ± 4.1; 6.3 ± 4.1; 6.0 ± 3.9) were similar among treatment arms. Fremanezumab reduced the number of days of acute headache medication use ([least-squares mean change vs. placebo] monthly: −1.4 [95% confidence interval: −1.84, −0.89], p < 0.001; quarterly: −1.3 [−1.76, −0.82], p < 0.001) and migraine-specific acute headache medication use (monthly: −2.2 [−2.80, −1.56], p < 0.001; quarterly: −2.2 [−2.81, −1.58], p < 0.001) compared with placebo. Fremanezumab also reduced nausea or vomiting, photophobia, and phonophobia compared with placebo. Conclusions: Fremanezumab reduced the need for acute headache medications, including migraine-specific medications, while treating migraine-associated symptoms in patients with episodic migraine. Trial registration: Clinicaltrials.gov NCT02629861 [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results